VEGFA and age-related macular degeneration: A retrospective study showed that anti-VEGF tachyphylaxis appeared in 38% of the AMD patients given bevacizumab, whereas 19% exhibited tachyphylaxis following treatment with ranibizumab.7 In a second retrospective review of 976 patients, the rate of tachyphylaxis was found to be 2%.8 In our current study, the rate of persistent cases, which may have been because of tachyphylaxis that occurred with the ranibizumab, was 17.0%.